Coastal communities are flooding more than we realize. Here's why.
'I view it as a harbinger of what's to come,' said Katherine Anarde, an assistant professor of coastal engineering at North Carolina State University and one of the lead authors of the study, published Monday in the journal Communications Earth & Environment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27 minutes ago
- Medscape
Can EBV-Related Penicillin Rashes Signal Long-Term Allergy?
TOPLINE: Nearly half of the adolescents and adults who developed rashes from penicillin during an Epstein-Barr virus (EBV) infection showed evidence of persistent drug hypersensitivity. METHODOLOGY: Patients with EBV infection sometimes receive antibiotics because the viral infection can mimic bacterial ones. A characteristic maculopapular rash — often considered self-limiting — can develop in this circumstance. Researchers analyzed data from 15 patients who developed a rash after taking penicillin during an EBV infection and later underwent drug allergy testing between 2012 and 2023 (median age at the time of the EBV-related rash, 18.5 years; 86.7% women). Drug allergy skin tests included intradermal tests with readings at 48 hours and patch tests with readings at 48 and 72 hours. The drugs tested were amoxicillin, amoxicillin/clavulanate, ampicillin, penicillin G, and cefuroxime. TAKEAWAY: Skin tests showed persistent sensitization in 46.7% of patients; five patients tested positive on both intradermal and patch tests. Of four patients who had been reexposed to penicillins before their allergy evaluation, three had recurrent drug hypersensitivity reactions, including one case of acute generalized exanthematous pustulosis. The median time to diagnostic evaluation after the initial EBV-related rash was 16 months (interquartile range, 4.3-111). Overall, 66.7% of patients experienced a rash lasting 7 days or longer. IN PRACTICE: 'Our findings underscore the importance of avoiding premature and uncritical labeling of patients as penicillin allergic or not, solely based on a rash occurring during EBV infection,' the authors of the study wrote. SOURCE: Lukas Joerg, MD, with Bern University Hospital in Bern, Switzerland, was the corresponding author of the study, which was published online on August 13 in International Archives of Allergy and Immunology. LIMITATIONS: The study was limited by its retrospective design, relatively small sample size, and lack of drug provocation testing in patients with negative skin tests. The researchers cautioned that negative skin test results may not exclude allergy, and some patients testing negative may still experience hypersensitivity upon rechallenge. Additionally, high rates of nonparticipation or loss to follow-up may have biased the findings. DISCLOSURES: The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
27 minutes ago
- Medscape
CAR T Excels in Second-Line Lymphoma Care
TOPLINE: Lisocabtagene maraleucel demonstrated superior efficacy with median event-free survival of 29.5 months compared to 2.4 months for standard of care in second-line large B-cell lymphoma (LBCL). The 36-month overall survival rate reached 63% for lisocabtagene maraleucel vs 52% for standard care, with progression-free survival rates of 51% vs 26.5%, respectively. METHODOLOGY: A total of 184 adults eligible for autologous stem cell transplantation were randomly assigned 1:1 to receive either lisocabtagene maraleucel or standard of care. Participants in the lisocabtagene maraleucel arm received a target dose of 100 × 10 6 chimeric antigen receptor-positive (CAR) T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation. chimeric antigen receptor-positive (CAR) T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation. Bridging therapy was permitted at investigator discretion for disease control during lisocabtagene maraleucel manufacturing. The study was conducted following Declaration of Helsinki guidelines, International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. TAKEAWAY: Median event-free survival was 29.5 months for lisocabtagene maraleucel vs 2.4 months for standard of care (hazard ratio [HR], 0.375; 95% CI, 0.259-0.542). Median progression-free survival was not reached for lisocabtagene maraleucel vs 6.2 months for standard of care, with 36-month rates of 51% vs 26.5%. The 36-month overall survival rate was 63% for lisocabtagene maraleucel vs 52% for standard of care. At 3-year follow-up, lisocabtagene maraleucel demonstrated superior, more durable efficacy vs standard of care with a favorable safety profile and no new safety signals. IN PRACTICE: 'These results provide long-term evidence to support liso-cel [lisocabtagene maraleucel] as an effective second-line treatment with curative potential for patients with primary refractory/early relapsed LBCL,' the authors of the study wrote. SOURCE: The study was led by Manali Kamdar, MD, MBBS, University of Colorado Cancer Center in Aurora, Colorado. It was published online in Journal of Clinical Oncology. LIMITATIONS: When interpreting overall survival data, the crossover design of the study needs to be considered. Additionally, the study was not powered to evaluate statistical differences in overall survival between treatment arms due to limited number of events in both groups. DISCLOSURES: The study was supported by Celgene, a Bristol Myers Squibb Company. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Washington Post
28 minutes ago
- Washington Post
August 21 morning weather update
The inside scoop on D.C. weather from the Capital Weather Gang. Get your D.C. area weather update in under a minute on weekday mornings.
